Diphtheria, Tetanus, and Acellular Pertussis (Tdap) Vaccine
Boostrix
- Dosage form
- Tablet
- Available strengths
- Not less than 2 IU diphtheria toxoid, 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg filamentous hemagglutinin, and 2.5 mcg pertactin per 0.5 mL dose
- Drug class
- Vaccine (active immunizing agent, combined diphtheria-tetanus-acellular pertussis)
- Common brand
- Boostrix
Clinical overview. The Diphtheria, Tetanus, and Acellular Pertussis (Tdap) Vaccine, sold as Boostrix, is a booster immunization against diphtheria, tetanus, and pertussis (whooping cough) given from age 4 onward and recommended during pregnancy to protect newborns. It is given as a single intramuscular injection, typically every 10 years, and commonly causes mild injection-site soreness, fatigue, and headache. Serious reactions such as anaphylaxis are rare but require immediate medical attention.
Indication
Common therapeutic uses
- This vaccine is used as a booster against diphtheria, tetanus, and pertussis in individuals from 4 years of age onward; it is not intended for a primary immunization series.
- This vaccine is used during pregnancy to provide passive protection against pertussis in early infancy, through antibodies passed from the mother to the baby.
- Booster doses against diphtheria and tetanus are generally recommended at 10-year intervals, or sooner for wound management in certain circumstances.
Pregnancy
Risk assessment and monitoring considerations
- This vaccine can be given during pregnancy, ideally during the third trimester, to protect the newborn against pertussis in early infancy, or according to national immunization recommendations.
- Data from clinical trials and post-marketing surveillance of vaccination during the second or third trimester have not shown any vaccine-related harm to the pregnancy or to the health of the fetus or newborn.
- Human data on vaccination during the first trimester are limited, but animal studies have not shown harmful effects on fertility, pregnancy, or fetal development.
Breastfeeding
Infant exposure considerations
- The safety of this vaccine during breastfeeding has not been formally evaluated, and it is not known whether its components pass into breast milk.
- This vaccine should be used during breastfeeding only when the potential benefit outweighs any potential risk.
Geriatrics
Dosing and tolerability considerations
- This vaccine is authorized for use in adults of all ages, including older adults, as part of routine 10-year booster vaccination.
- Repeated vaccination in adults over 40 years of age on an accelerated schedule has been associated with a small increase in local injection site reactions such as pain, redness, and swelling.
Pediatrics
Use in children and adolescents
- This vaccine is indicated for booster use from 4 years of age onward; it is not authorized for infants or for the primary vaccination series in young children.
- In children with progressive neurological disorders, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy, it is generally better to defer the pertussis component of vaccination until the condition is corrected or stabilized.
Dosage & Administration
Practical dosing and administration
- A single 0.5 mL dose is given by deep intramuscular injection.
- The vaccine should be well shaken before use to obtain a uniform, turbid, white suspension.
- The vaccine should not be mixed with other vaccines in the same syringe.
- Booster doses against diphtheria and tetanus are generally repeated every 10 years, as per official recommendations; it is not necessary to restart the primary vaccination series if the recommended interval between boosters is exceeded.
- For tetanus prophylaxis after a wound, the need for a booster dose depends on the type of wound and the number of prior tetanus doses received.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Cases of vaccine overdose have been reported during post-marketing surveillance.
- Adverse events following an overdose were similar in nature to those seen with a normal, correctly administered dose.
Common side effects
Frequently reported tolerability concerns
- Pain, redness, or swelling at the injection site may occur.
- Fatigue may occur.
- Headache may occur.
- Malaise (a general feeling of being unwell) may occur.
- Fever may occur.
- Dizziness may occur.
- Nausea or other gastrointestinal upset may occur.
- Muscle aches, joint pain, or joint stiffness may occur.
- Irritability may occur, particularly in younger children.
- Sleepiness (somnolence) may occur, particularly in younger children.
- Loss of appetite may occur, particularly in younger children.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Severe allergic reactions, including anaphylaxis, can occur after vaccination, which is why observation for 30 minutes after the injection is recommended.
- Extensive swelling of the vaccinated limb has been reported.
- Fainting (syncope) can occur as a response to the injection itself, sometimes before or shortly after vaccination.
- Seizures, with or without fever, have been reported rarely.
- Hives (urticaria) and angioedema have been reported.
- A causal link has been found between tetanus toxoid-containing vaccines and Guillain-Barre syndrome or brachial neuritis in rare cases.
- In infants and young children, a temperature of 40 degrees C or higher, an episode of limpness and unresponsiveness, or persistent crying lasting 3 hours or more within 48 hours of vaccination should be reported before further pertussis-containing doses are given.
- Seek urgent medical attention for difficulty breathing, swelling of the face or throat, signs of a severe allergic reaction, or a seizure following vaccination.
Use with caution
Situations requiring closer assessment
- Use with caution in individuals with thrombocytopenia or a bleeding disorder, since bleeding can occur at the injection site; firm pressure should be applied for at least 2 minutes after the injection.
- Use with caution in individuals with a history of Guillain-Barre syndrome within 6 weeks of a prior tetanus-toxoid-containing vaccine, weighing the benefits and risks before giving another dose.
- Use with caution in children with progressive neurological disorders, where deferring the pertussis component may be appropriate.
- Vaccination should be postponed in individuals with an acute, severe febrile illness; a minor infection is not a reason to delay vaccination.
- Individuals receiving immunosuppressive therapy or with immunodeficiency may not develop a full immune response to the vaccine.
- This vaccine must never be given intravenously; it is for intramuscular injection only.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in individuals with known hypersensitivity to any component of the vaccine.
- Contraindicated in individuals who have shown signs of hypersensitivity after a previous dose of a diphtheria, tetanus, or pertussis vaccine.
- Contraindicated in individuals who developed encephalopathy of unknown cause within 7 days of a previous dose of a pertussis-containing vaccine.
- Contraindicated in individuals who experienced transient low platelet counts (thrombocytopenia) or neurological complications after an earlier diphtheria or tetanus vaccine.
Drug interactions
Clinically relevant combinations
- This vaccine can be given at the same time as other vaccines or immunoglobulin, as long as they are given at separate injection sites.
- Individuals receiving immunosuppressive therapy, such as chemotherapy or high-dose corticosteroids, may have a reduced immune response to this vaccine.
- No specific drug interactions with non-vaccine medications have been established.
Food interactions
Meal-related administration
- Not applicable; this vaccine is given by injection, so food and meal timing do not affect its use.
Time of administration
Practical scheduling
- This vaccine is given as a single injection during a scheduled healthcare visit, not as a self-administered, time-of-day-specific dose; your healthcare provider will determine the appropriate timing based on your vaccination history.
Storage
Product handling
- Store at 2°C to 8°C; do not freeze, and discard the vaccine if it has been frozen.
- Protect from light.
- Do not use beyond the expiry date printed on the label.
Patient take-away
Key counselling points for a quick closing summary
- This vaccine boosts your protection against diphtheria, tetanus, and pertussis (whooping cough) and, when given during pregnancy, also helps protect your newborn during early infancy.
- Mild soreness, redness, fatigue, or headache after the injection are common and usually resolve on their own within a few days.
- Seek urgent medical attention for signs of a severe allergic reaction, such as difficulty breathing or facial swelling, or for a seizure following vaccination.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.